Comparison Overview

Hengrui Pharma Co.,Ltd

VS

MSD

Hengrui Pharma Co.,Ltd

Pudong New Area, Shanghai, China, No. 1288, Haike Road, Shanghai, Shanghai, CN, None
Last Update: 2025-11-20
Between 800 and 849

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma’s therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 19 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 3,527
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

MSD

90 E Scott Ave, Rahway, New Jersey, US, 07065
Last Update: 2025-11-26
Between 750 and 799

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 35,519
Subsidiaries: 34
12-month incidents
1
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/jiangsu-hengrui-pharmaceuticals.jpeg
Hengrui Pharma Co.,Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Hengrui Pharma Co.,Ltd
100%
Compliance Rate
0/4 Standards Verified
MSD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Hengrui Pharma Co.,Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

MSD has 16.28% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — Hengrui Pharma Co.,Ltd (X = Date, Y = Severity)

Hengrui Pharma Co.,Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — MSD (X = Date, Y = Severity)

MSD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/jiangsu-hengrui-pharmaceuticals.jpeg
Hengrui Pharma Co.,Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
Incidents

Date Detected: 9/2025
Type:Breach
Attack Vector: unauthorized access, supply chain compromise
Blog: Blog

FAQ

Hengrui Pharma Co.,Ltd company demonstrates a stronger AI Cybersecurity Score compared to MSD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

MSD company has historically faced a number of disclosed cyber incidents, whereas Hengrui Pharma Co.,Ltd company has not reported any.

In the current year, MSD company has reported more cyber incidents than Hengrui Pharma Co.,Ltd company.

Neither MSD company nor Hengrui Pharma Co.,Ltd company has reported experiencing a ransomware attack publicly.

MSD company has disclosed at least one data breach, while Hengrui Pharma Co.,Ltd company has not reported such incidents publicly.

Neither MSD company nor Hengrui Pharma Co.,Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Hengrui Pharma Co.,Ltd company nor MSD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Hengrui Pharma Co.,Ltd nor MSD holds any compliance certifications.

Neither company holds any compliance certifications.

MSD company has more subsidiaries worldwide compared to Hengrui Pharma Co.,Ltd company.

MSD company employs more people globally than Hengrui Pharma Co.,Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Hengrui Pharma Co.,Ltd nor MSD holds SOC 2 Type 1 certification.

Neither Hengrui Pharma Co.,Ltd nor MSD holds SOC 2 Type 2 certification.

Neither Hengrui Pharma Co.,Ltd nor MSD holds ISO 27001 certification.

Neither Hengrui Pharma Co.,Ltd nor MSD holds PCI DSS certification.

Neither Hengrui Pharma Co.,Ltd nor MSD holds HIPAA certification.

Neither Hengrui Pharma Co.,Ltd nor MSD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.

Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H